Approximately 60 to 70% of breast cancers express the estrogen receptor (ER+), 10 to 15% are ERBB2-amplified (HER2+), and 10 to 15% are triple-negative breast cancers (TNBC) that are ER-, PR-, and Her2-. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.